QTERN (saxagliptin/dapagliflozin)

QTERN™ is a fixed dose combination of saxagliptin and dapagliflozin and is indicated in adults aged 18 years and older with type 2 diabetes mellitus1

Mode of Action

QTERN™ combines dapagliflozin (an SGLT2 inhibitor) and saxagliptin (a DPP-4 inhibitor) with complementary mechanisms of action to improve glycaemic control.

 

Qtern mode of action
Qtern mode of action

Combines complementary mechanisms of action1

 

SGLT2 insulin-independent mechanism:6

  • SGLT2 inhibition reduces glucose reabsorption by the kidneys and increases glucose excretion in the urine.
  • SGLT2 inhibitors act on a pathway independent of the level of β cell function to provide a glucose-lowering effect.

Benefits:6

  • HbA1c reduction
  • Secondary benefit of weight loss*
  • Secondary benefit of systolic BP reduction*
  • Low risk of hypoglycaemia**
  • Insulin independent MOA.

*FORXIGA® and QTERN™ are not indicated for the management of weight loss or high blood pressure. Weight change was a secondary endpoint in clinical trials.1, 6  
**FORXIGA® 10 mg is associated with low risk of hypoglycaemia when added to metformin. Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with FORXIGA®.6
If QTERN™ is used in combination with insulin secretagogue (sulphonylurea), a reduction in the dose of sulphonylurea may be required to minimise the risk of hypoglycaemia.1

 

DPP-4 insulin-dependent mechanism:8

  • DPP-4 inhibition increases concentrations of the incretin hormones GLP-1 and GIP, which result in a glucose-dependent increase in insulin secretion, reduction in glucagon secretion, improved glucose uptake in peripheral tissue and reduced hepatic glucose production.

Benefits:1

  • Additional HbA1c reduction
  • Low risk of hypoglycaemia
  • Generally well tolerated.

Insulin or an insulin secretagogue, such as sulphonylureas, cause hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with ONGLYZA®.8

If QTERN™ is used in combination with insulin secretagogue (sulphonylurea), a reduction in the dose of sulphonylurea may be required to minimise the risk of hypoglycaemia.1